{"a":[{"_":"Lilly's Zepbound remains physicians' favorite, even as oral obesity launches altar landscape","$":{"href":"/pharma/even-launch-obesity-pills-lillys-zepbound-remains-overwhelming-favorite-among-physicians","hreflang":"en"}}]}

Summary

Eli Lilly's Zepbound remains the preferred weight loss drug among physicians despite increased competition from oral obesity treatments, according to a Spherix Global Insights survey showing injected treatments maintain significant advantage over newer oral options.